Investigational Alzheimer’s Therapy NNI-362 Receives FDA Approval to Enter Phase 1 Clinical Studies

Home / Alzheimer's / Investigational Alzheimer’s Therapy NNI-362 Receives FDA Approval to Enter Phase 1 Clinical Studies